April 19, 2018 | Katie Neith
Researchers at Beckman Research Institute of City of Hope use novel technology to add new functionalities to already potent proteins.
Researchers Use Nanoparticles to Test Treatment for Liver Disease
June 25, 2018 | Katie Neith
In an effort to improve options for those with liver cancer, a group of researchers have identified a way of potentially treating a broad range of liver diseases and perhaps even other types of cancer.
$2 million grant awarded to City of Hope to promote critical research on aging and cancer
June 1, 2018 | Letisia Marquez
The National Institute of Aging has awarded $2 million to City of Hope to establish a national research infrastructure that will facilitate and support significant innovative projects across the country addressing aging and cancer.
TGen Spotlight: New Study Tackles Sports-Related Concussions
October 16, 2017 | City of Hope
TGen-Riddell partnership results could help future studies lead to advanced methods of injury and disease detection
Leukemia and Autoimmune Disease Targeted in City of Hope-Caltech Collaboration
October 10, 2017 | Wayne Lewis
The Caltech-City of Hope Biomedical Research Initiative combines the strengths of these top Southern California research institutions to accelerate scientific investigations and fight disease.
Behnam Badie given $2.1 million R01 grant to study RAGE
May 3, 2017 | Denise Heady
What started as an unplanned lunch date has turned into a potential breakthrough in the treatment of gliomas – a fast-growing, and often deadly type of brain tumor.
City of Hope Partners with Scripps to Find New Treatment for HIV
May 2, 2017 | Michael Easterling
A team from The Scripps Research Institute (TSRI) in La Jolla, California, is working with City of Hope’s Center for Gene Therapy to test a cell culture resistant to the HIV virus for efficacy and safety. If testing goes as planned, TSRI and City of Hope investigators may have identified a new treatment for HIV.
TGen Identifies Promising New Compound for Treatment of Glioblastoma
April 20, 2017 | City of Hope
A study led by scientists at the Translational Genomics Research Institute (TGen) has identified a chemical compound called Aurintricarboxylic Acid (ATA), shown to block the chemical cascade that otherwise allows glioblastoma cells to resist both chemo and radiation therapy.